placeholder image

DR Alison Every


  • Host response to Helicobacter pylori (NKT cells, inflammation)
  • Immune memory resilience (T-cell memory)
  • Vaccine development (Helicobacter pylori, adjuvants)



Member of

  • Australasian Society for Immunology. Ordinary member 2001 -


Selected publications


Investigator on

Additional Grant Information

  • FIMSA Travel grant
    To attend the 4th Congress of the Federation of Immunology Societies of Asia-Oceania, Taipei, Taiwan, October 17-20, 2008

    CASS Foundation Travel Grant
    To attend the 13th International Congress of Mucosal Immunology, Tokyo, Japan, July 9-12, 2007

    Keystone Travel Grant
    To attend Translational Medicine in Autoimmunity (Keystone, A4), Big Sky, Montana, USA, January, 2005

    Australasian Society for Immunology Travel Grant
    To attend the 33rd Annual Scientific Meeting of the Australasian Society for Immunology, Perth, Australia, December 2003

    Immunology of Diabetes Society Travel Grant
    To attend the 6th International Congress of the Immunology of Diabetes Society, Copper Mountain, Colorado, USA, October, 2002



Education and training

  • Dr, Walter and Eliza Hall Institute of Medical Research 2005



Available for supervision

  • Y

Supervision Statement

  • My research is centred around two major themes:

    1. The inflammatory response to Helicobacter infection
    Over 50% of the World's population is infected with Helicobacter pylori and yet only about 15-20% ever develop overt diseases such as peptic ulcer, gastric mucosal-associated lymphoid tissue lymphoma or gastric cancer. We seek to understand why it is that some individuals develop such strong inflammation, while others don't. Specifically we are focussing on how NKT cells modulate the inflammatory response to Helicobacter infection.

    2. Vaccines
    The potential for a successful outcome following vaccination depends on generation of robust and resilient host immune response that can be directed specifically against a pathogen. In designing new vaccines we think about how the pathogen interacts with its host and in turn, how we can harness this knowledge to develop novel, efficacious vaccines. A major focus of this approach is discovery and validation of novel vaccine adjuvants, which can boost immune responses and improve vaccine efficacy.